Monoclonal Antibody Therapy for Senior Cat Pain Management

A new class of monoclonal antibody medications is transforming chronic pain management in senior cats, offering sustained relief with minimal side effects compared to traditional analgesics.

Key Facts

Feline osteoarthritis affects an estimated 40% of cats over 10 years of age
Traditional NSAIDs carry significant kidney and liver risks in cats with concurrent organ disease
Anti-nerve growth factor monoclonal antibodies provide approximately 4 weeks of pain relief per injection
Clinical trials show meaningful improvement in mobility and activity in arthritic cats after treatment
Cats are notoriously skilled at hiding chronic pain, making owner recognition of improvement particularly valuable
Monthly subcutaneous injections are well-tolerated and can be administered in a low-stress veterinary visit

Welfare Considerations

Feline chronic pain has historically been undertreated due to the limited analgesic options safe for long-term use in cats. Many cats with osteoarthritis live with significant but unrecognized pain because they show subtle signs — reduced jumping, less grooming of hindquarters, or behavioral changes owners may attribute to aging. The emergence of anti-nerve growth factor monoclonal antibodies represents a significant welfare advance, providing safe, effective, and durable analgesia for this common condition. Identifying pain through validated feline grimace scales and owner questionnaires combined with access to effective treatment represents a meaningful improvement in the quality of life for millions of senior cats.

What You Can Do

Ask your veterinarian about pain assessment tools like the Feline Grimace Scale for your senior cat
Schedule bi-annual wellness exams for cats over 10 to catch painful conditions early
Ask specifically about monoclonal antibody pain therapy if your older cat shows any mobility changes
Learn the subtle signs of feline chronic pain: reduced jumping, hesitation on stairs, less grooming